Dermatitis, Atopic: Clinical Trials

937 completed, 151 recruiting, 129 unknown, 108 terminated. 401 Phase 2, 289 Not applicable, 233 Phase 3, 225 Phase 1, 136 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	401	Completed 267, Terminated 45, Recruiting 32, Active not recruiting 23, Unknown 15, Not yet recruiting 8, Withdrawn 8, Enrolling by invitation 3
Not applicable	289	Completed 168, Unknown 41, Recruiting 26, Terminated 19, Withdrawn 14, Not yet recruiting 12, Active not recruiting 7, Enrolling by invitation 2
Phase 3	233	Completed 155, Recruiting 16, Unknown 14, Not yet recruiting 13, Active not recruiting 12, Withdrawn 11, Terminated 9, Enrolling by invitation 2, Suspended 1
Phase 1	225	Completed 154, Recruiting 21, Terminated 20, Unknown 11, Withdrawn 8, Not yet recruiting 6, Active not recruiting 4, Enrolling by invitation 1
Phase 4	136	Completed 87, Terminated 12, Unknown 12, Not yet recruiting 10, Recruiting 7, Active not recruiting 4, Withdrawn 4
Early Phase 1	12	Completed 7, Unknown 2, Enrolling by invitation 1, Terminated 1, Withdrawn 1

Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
Educational Eczema Video Intervention in-clinic video intervention, at home video intervention - Eczema	Not applicable	Withdrawn	Boston Children's Hospital		2027-01-01	2026-10-19
Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis	Phase 4	Not yet recruiting	Wake Forest University Health Sciences	50	2026-12-01	2026-09-04
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Digital App Mindfulness Meditation, Mindfulness Meditation Sheet - Atopic Dermatitis, Eczema	Not applicable	Recruiting	Weill Medical College of Cornell University	40	2026-11-15	2026-10-23
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis	Phase 4	Not yet recruiting	Forefront Dermatology S.C	250	2026-11-11	2026-10-02
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	20	2026-11-08	2026-11-03
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Almirall, S.A.	230	2026-11-01	2026-10-14
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis NOR-101, Placebo - Atopic Dermatitis (AD)	Phase 1	Not yet recruiting	North Immunology Inc.	96	2026-11-01	2026-10-29
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis Dupilumab - Atopic Dermatitis	Phase 4	Not yet recruiting	Sanofi	56	2026-10-28	2026-10-29
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis 0.5% AR100DP1, Placebo - Dermatitis Atopic	Phase 2	Recruiting	Arjil Pharmaceuticals LLC	40	2026-10-21	2026-11-03
Observational Analytical Validation Study of the Replior ScratchSense Scratch and sleep research tracking - Atopic Dermatitis, Other Pruritic Dermatological		Recruiting	Replior AB	35	2026-10-12	2026-11-02
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis Melatonin, Standard Treatment for Atopic Dermatitis - Atopic Dermatitis	Not applicable	Not yet recruiting	Can Tho University of Medicine and Pharmacy	130	2026-10-10	2026-09-25
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis	Phase 3	Recruiting	Galderma R&D	240	2026-10-08	2026-10-16
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis LT-002-158, Placebo - Atopic Dermatitis (AD)	Phase 2	Recruiting	Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.	160	2026-10-01	2026-10-26
Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis Atopic Dermatitis (AD), Scabies		Not yet recruiting	Istanbul Medeniyet University	51	2026-10-01	2026-09-15
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases Psoriasis, Eczema/Atopic Dermatitis		Not yet recruiting	Medisch Spectrum Twente	1000	2026-10-01	2026-09-04
Abrocitinib Dose Tapering in Patients With Atopic Dermatitis Abrocitinib - Atopic Dermatitis	Phase 4	Not yet recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	100	2026-10-01	2026-09-29

Showing 20 of 1514. Sign in to see all of them.

Narrower conditions

Eczema (325)  ·  Dermatitis (89)  ·  Pruritus (73)  ·  Psoriasis (72)  ·  Skin Diseases (55)  ·  Asthma (50)  ·  Hypersensitivity (40)  ·  Food Hypersensitivity (34)  ·  Rhinitis, Allergic (27)  ·  Hidradenitis Suppurativa (21)  ·  Immune System Diseases (20)  ·  Skin Diseases, Eczematous (19)  ·  Vitiligo (18)  ·  Alopecia Areata (16)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1514)  ·  Skin and Connective Tissue Diseases (1513)  ·  Genetic Diseases, Inborn (1505)  ·  Hypersensitivity, Immediate (1501)  ·  Skin Diseases, Genetic (1498)  ·  Skin Diseases, Eczematous (1495)  ·  Immune System Diseases (1494)  ·  Hypersensitivity (1474)  ·  Skin Diseases (1459)  ·  Dermatitis (1425)  ·  Pathological Conditions, Signs and Symptoms (111)  ·  Signs and Symptoms (85)  ·  Skin Diseases, Papulosquamous (79)  ·  Skin Manifestations (74)  ·  Respiratory Tract Diseases (67)

Interventions

dupilumab (85)  ·  pimecrolimus (38)  ·  abrocitinib (31)  ·  lebrikizumab (26)  ·  upadacitinib (26)  ·  Adrenal Cortex Hormones (23)  ·  Tacrolimus (22)  ·  tralokinumab (21)  ·  crisaborole (19)  ·  baricitinib (16)  ·  Cyclosporine (14)  ·  Ointments (14)  ·  difamilast (14)  ·  nemolizumab (13)  ·  ruxolitinib (12)

Sponsors

Pfizer (57)  ·  Sanofi (37)  ·  LEO Pharma (36)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (35)  ·  AbbVie (31)  ·  Eli Lilly and Company (29)  ·  Regeneron Pharmaceuticals (29)  ·  Novartis Pharmaceuticals (17)  ·  Astellas Pharma Inc (16)  ·  Incyte Corporation (16)  ·  Northwestern University (16)  ·  Amgen (15)  ·  GlaxoSmithKline (15)  ·  Keymed Biosciences Co.Ltd (15)  ·  Bayer (14)

Countries

United States (613)  ·  Germany (223)  ·  Canada (212)  ·  China (180)  ·  Poland (154)  ·  France (122)  ·  United Kingdom (121)  ·  Japan (116)  ·  Spain (111)  ·  Australia (105)  ·  Italy (79)  ·  South Korea (79)  ·  Czechia (73)  ·  Netherlands (72)  ·  Taiwan (67)

Top investigators

Robert Bissonnette, MD (8)  ·  Amy Paller, MD (7)  ·  Donald Leung, MD, PhD (6)

Results publications

PMID 39588375, PMID 33826132, PMID 42162528, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40993471, PMID 33165005, PMID 39104653, PMID 40028832, PMID 31066001, PMID 33453450, PMID 34142350, PMID 35061234, PMID 35342978, PMID 35567671, PMID 35636689, PMID 36749121, PMID 36808602, PMID 38777187, PMID 40555305, PMID 41118053, PMID 25006719, PMID 31407311, PMID 31424712, PMID 33658996, PMID 33954933, PMID 33982267, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35462428, PMID 35714786, PMID 35763326, PMID 36152216, PMID 36525340, PMID 36754548, PMID 37043227, PMID 37247226, PMID 37949351, PMID 37988255, PMID 39008191, PMID 39110139, PMID 39441580, PMID 40085349, PMID 40383273

NIH funding

2018 (31), 2023 (18), 2017 (13), 2025 (11), 2019 (10), 2014 (8), 2016 (7), 2015 (5), 2008 (3), 2009 (2), R21AR062357 (2), 2004 (1), R01AR071057 (1), R01AR073486 (1), R01AR082831 (1)